Recorded Webinar with Dr. Bernard Thébaud: Recycling Matters: Cord-Derived Stem Cell Treatment of Neonatal Diseases
Share the Science
Watch the recorded webinar to hear Dr. Bernard Thébaud, neonatologist at the Children’s Hospital of Eastern Ontario and a senior scientist with the Ottawa Hospital Research Institute and Children’s Hospital of Eastern Ontario Research Institute, discuss using stem cell therapy to improve lung disease and repair organ damage in premature infants.
Dr. Thébaud’s research focuses on the clinical translation of stem-cell-based therapies for neonatal diseases. Continuous improvements in perinatal care have increased survival rates of premature infants, making the task of protecting premature lungs from injury increasingly challenging. The same holds true for other maturing organs, such as the brain or the gut. Premature infants are at risk of developing chronic lung disease or bronchopulmonary dysplasia (BPD). The long-term consequences of early interference with lung development are incompletely understood and may reach beyond childhood. Currently, there are no specific treatments to prevent complications of extreme prematurity.
Recent insight into stem cell biology has sparked interest for stem cells to repair damaged organs. Over the past 5 years, many investigators have harnessed the repair capabilities of a variety of stem cells in experimental models of BPD. While further pre-clinical studies are needed, this webinar highlights the exciting potential for umbilical-cord-derived stem-cell-based therapies for the prevention or treatment of BPD and other complications.
You Will Learn:
- The public health challenges of extreme prematurity
- Different types of stem/progenitor cells present in perinatal tissue
- The rationale for using cell-based therapies for complications of extreme prematurity
- The therapeutic potential of these cells to prevent complications of extreme prematurity
Bernard Thébaud, M.D., Ph.D., discusses using cord-derived stem cells to treat neonatal lung disease and other complications in premature babies and how these therapies can improve the overall outcome.
Dr. Bernard Thébaud is a clinician-scientist recruited to Ottawa from Edmonton in 2012 to accelerate the translation of stem-cell-based therapies for lung diseases. Dr. Thébaud is a senior scientist with the Ottawa Hospital Research Institute and a neonatologist with the Children’s Hospital of Eastern Ontario, where he provides care to critically ill newborns. He is also a professor of Pediatrics at the University of Ottawa.
Dr. Thébaud obtained his medical degree at the University Louis Pasteur in Strasbourg, France in 1991 and trained in pediatrics and neonatology at the University Paris V in Paris, France, where he also obtained his M.Sc. and Ph.D. before completing a 2-year post-doctoral fellowship at the University of Alberta.
Dr. Thébaud studies the mechanisms of lung development, injury and repair in order to design new treatments for incurable lung diseases. He has set out an ambitious research program in order to study clinically relevant questions for translation into real-life applications. Over the next five years, his goal is to bring safe and effective cell-based therapies for lung diseases into the clinic and thereby create vast improvements in patient outcomes.
Dr. Thébaud has participated on numerous peer review committees and scientific advisory boards at the international, national and provincial level, including NIH and CIHR. He has more than 100 peer-reviewed publications and given more than 50 lectures at leading international meetings and institutions over the past five years. He received the “Rising Star in Perinatal Research” award from the CIHR Institute for Human Development, Child and Youth Health in 2008, and the “Best in Current Canadian Child Health Research” Sanofi Pasteur Research Award in 2007. Dr. Thébaud currently holds the University of Ottawa Partnership Research Chair in Regenerative Medicine.
Mediware and Save the Cord Foundation are proud to bring you this exclusive speaker series to discuss the topics you and your peers are most interested in. Join us as we feature your colleagues to discuss their latest research, opinions on industry news and so much more. We look forward to having you on board for this exciting series!